Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Mandorfer, M; Payer, BA; Niederecker, A; Lang, G; Aichelburg, MC; Strassl, R; Boesecke, C; Rieger, A; Trauner, M; Peck-Radosavljevic, M; Reiberger, T.
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
AIDS Patient Care STDS. 2014; 28(5): 221-227.
Doi: 10.1089/apc.2013.0359
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Trauner Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim of this study was to assess the therapeutic potential of telaprevir (TPV)/boceprevir (BOC)-based triple-therapy in a complete cohort of HIV/chronic hepatitis C co-infected patients (HIV/HCV). Moreover, a case series of four HIV/HCV genotype (HCV-GT)1 patients with rapid virologic response (RVR), who received only 28 weeks of BOC-based triple-therapy (BOCW28), was reported. 290/440 HIV-positive patients with positive HCV serology had at least one visit during the past 2 years, 142/290 had target detectable HCV-RNA with 64% (82/142) carrying HCV-GT1. While 18 HIV/HCV-GT1 displayed contraindications, 45% (64/142) of HIV/HCV were eligible for triple-therapy. Insufficiently controlled HIV-infection despite combined antiretroviral therapy (cART) (HIV-RNA <50 copies/mL: 73% vs. 22%; p<0.001) and liver cirrhosis (31% vs. 8%; p=0.025) were overrepresented among patients with contraindications for triple-therapy. Low treatment uptake rates (39% (25/64)) during the first 2 years of triple-therapy availability suggest that its benefit in HIV/HCV co-infected patients might fall short of expectations. Modification of cART or TPV dose adjustment would have been necessary in 61% and 84% of HIV/HCV-GT1 on cART eligible for triple-therapy using TPV and BOC, respectively, suggesting that drug-drug interactions with cART complicate management in the majority of patients. All four BOCW28 patients achieved a sustained virologic response. Prospective studies are necessary to validate our observations on the shortening of treatment duration in HIV/HCV-GT1 with RVR.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antiviral Agents - administration & dosage
- Antiviral Agents -
- Coinfection - drug therapy
- Drug Therapy, Combination - methods
- Female -
- Genotype -
- HIV Infections - complications HIV Infections - drug therapy
- HIV-1 - genetics
- Hepatitis C, Chronic - drug therapy
- Humans -
- Interferon-alpha - administration & dosage
- Male -
- Middle Aged -
- Oligopeptides - administration & dosage
- Proline - administration & dosage Proline - analogs & derivatives
- RNA, Viral - blood
- Retrospective Studies -
- Ribavirin - administration & dosage
- Treatment Outcome -
- Young Adult -